4.4 Article

Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma

Journal

DIGESTIVE DISEASES AND SCIENCES
Volume 61, Issue 9, Pages 2568-2577

Publisher

SPRINGER
DOI: 10.1007/s10620-016-4158-6

Keywords

Hepatocellular carcinoma; Hepatic stellate cell; Hypoxia; Crosstalk; PI3K/Akt pathway

Funding

  1. National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea [1420050]
  2. Liver Research Foundation of Korea

Ask authors/readers for more resources

Crosstalk between tumor cells and their microenvironment plays a crucial role in the progression of hepatocellular carcinoma (HCC). Hypoxia, a common feature of advanced HCC, has been shown to modulate the evolution of the tumor microenvironment. In this study, we investigated the effect of hypoxia on tumor-stroma crosstalk in HCC. Human HCC cell lines (Huh-BAT, SNU-475) were cocultured with an activated human hepatic stellate cell line (HSCs; LX-2) under either normoxic or hypoxic conditions. Cell growth was evaluated with the MTS assay. Apoptotic signaling cascades were assessed by immunoblot analysis. Expression of CD31 and phosphorylated (p-) Akt in HCC tissues was detected by immunohistochemistry. Coculturing HCC cells with HSCs under hypoxic conditions enhanced their proliferation, migration, and resistance to bile acid (BA)-induced apoptosis compared to coculturing under normoxic conditions. Under hypoxia, of various HSC-derived growth factors, PDGF-BB was the most up-regulated, leading to the activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in HCC cells. Immunohistochemical study also revealed that p-Akt was highly expressed in hypoxic, hypovascular HCC as compared to hypervascular HCC. Neutralizing antisera to PDGF-BB or a PI3K inhibitor attenuated the proliferation of HCC cells cocultured with HSCs, and sensitized HCC cells to BA-induced apoptosis, especially under hypoxic conditions. In conclusion, hypoxic HSC-derived PDGF-BB stimulates the proliferation of HCC cells through activation of the PI3K/Akt pathway, while the inhibition of PDGF-BB or PI3K/Akt pathways enhances apoptotic cell death. Targeting tumor-stroma crosstalk might be a novel therapy in the management of human HCCs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Radiology, Nuclear Medicine & Medical Imaging

Effectiveness of US Surveillance of Hepatocellular Carcinoma in Chronic Hepatitis B: US LI-RADS Visualization Score

Min Kyung Park, Dong Ho Lee, Bo Yun Hur, Hyung-Chul Lee, Yun Bin Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee

Summary: This study assessed the detection power of ultrasound (US) and the occurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) based on the US Liver Imaging Reporting and Data System (LI-RADS) visualization score. The results showed that patients with suboptimal visualization (score B or C) had a higher risk of HCC and a higher rate of false-negative findings on US.

RADIOLOGY (2023)

Article Medicine, General & Internal

The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic status in Korea: A nationwide population-based study

Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu

Summary: This study aimed to investigate whether the association between alcohol consumption and hepatocellular carcinoma (HCC) risk differs by fasting serum glucose level and diabetes. The results showed that mild-to-moderate alcohol consumption increased the risk of HCC in all glycemic statuses, but the risk was highest in patients with diabetes.

PLOS MEDICINE (2023)

Article Medicine, General & Internal

Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease

Jeong-Ju Yoo, Man Young Park, Eun Ju Cho, Su Jong Yu, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon

Summary: This study investigates the effect of smoking on the incidence of hepatocellular carcinoma (HCC) and cardiovascular disease (CVD) in patients with metabolic-associated fatty liver disease (MAFLD). The analysis of a Korean health screening database shows that smoking significantly increases the risk of HCC and CVD in MAFLD patients. Complete smoking cessation is highly recommended for individuals with MAFLD.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Oncology

Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study

Jihye Kim, Moon Haeng Hur, Seung Up Kim, Jin-Wook Kim, Dong Hyun Sinn, Hyun Woong Lee, Moon Young Kim, Jae Youn Cheong, Yong Jin Jung, Han Ah Lee, Young-Joo Jin, Jun Sik Yoon, Sung-Jae Park, Chang Hun Lee, In Hee Kim, June Sung Lee, Young Youn Cho, Hyung Joon Kim, Soo Young Park, Yeon Seok Seo, Hyunwoo Oh, Dae Won Jun, Mi Na Kim, Young Chang, Jae Young Jang, Sang Youn Hwang, Yoon Jun Kim

Summary: This study compared the effectiveness of entecavir and tenofovir disoproxil fumarate in preventing hepatocellular carcinoma among patients with chronic hepatitis B. The study found that the two antivirals had similar efficacy in preventing HCC and had comparable rates of other outcomes. However, the tenofovir disoproxil fumarate group had more side effects, leading to some patients needing to switch initial antiviral medications.

CANCERS (2023)

Article Gastroenterology & Hepatology

Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B

Cheol-Hyung Lee, Yun Bin Lee, Hyemi Moon, Jong-Won Chung, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung-Hwan Yoon

Summary: This study investigated the associations between aspirin use and risks of hepatocellular carcinoma (HCC), liver-related mortality, and major bleeding in non-cirrhotic patients with chronic hepatitis B (CHB). The results showed that aspirin use was associated with reduced risks of HCC and liver-related death, without an increase in the risk of major bleeding, in patients with CHB and a higher metabolic risk factor burden.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks

Scott K. Fung, Calvin Q. Pan, Grace Lai-Hung Wong, Wai-Kay Seto, Sang Hoon Ahn, Chi-Yi Chen, Hie-Won L. Hann, Maciej S. Jablkowski, Yoon Jun Kim, Cihan Yurdaydin, Cheng-Yuan Peng, Tuan Nguyen, Hiroshi Yatsuhashi, John F. Flaherty, Leland J. Yee, Frida Abramov, Hongyuan Wang, Dzhamal Abdurakhmanov, Young-Suk Lim, Maria Buti

Summary: Patients with CHB who switch from TDF to TAF show changes in lipid profiles but no significant impact on cardiovascular risk.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Oncology

Impact of Low Skeletal Muscle Mass on Long-Term Outcomes in Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization: A Retrospective Multi-Center Study

Heechul Nam, Hyun Yang, Ho Soo Chun, Han Ah Lee, Joon Yeul Nam, Jeong Won Jang, Yeon Seok Seo, Do Young Kim, Yoon Jun Kim, Si Hyun Bae

Summary: The study aimed to identify prognostic factors, including pre-treatment low skeletal muscle mass (LSMM), for survival outcomes in patients with hepatocellular carcinoma (HCC) undergoing trans-arterial radioembolization (TARE).

CANCERS (2023)

Article Medicine, General & Internal

Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study

Heejoon Jang, Su Jong Yu, Hong Ghi Lee, Tae Min Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Jung-Hwan Yoon, Yoon Jun Kim

Summary: The optimal duration of prophylactic antiviral therapy in patients with resolved HBV receiving rituximab is unclear. This study found that there is no significant difference in HBV reactivation between the 6-month and 12-month prophylactic TDF groups after completion of rituximab-based chemotherapy.

JOURNAL OF KOREAN MEDICAL SCIENCE (2023)

Article Medicine, General & Internal

Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients

Ji Min Han, Youngil Koh, Sung Hwan Kim, Sung Yun Suh, Yoon Sook Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Hye Sun Gwak

Summary: This retrospective study evaluated the records of liver cirrhosis patients receiving dalteparin for portal vein thrombosis treatment. No history of variceal bleeding and newly developed thrombus before treatment were predictive factors associated with increased treatment response. Delay in starting treatment (more than three months or six months) was associated with a higher risk of relapse. Individualized dosing regimen (based on body weight) was more effective than fixed dosing regimen, with no observed bleeding complications.

MEDICINA-LITHUANIA (2023)

No Data Available